2023-11-15T11:16:02-06:00 2022-12-31 946214841 ARMANINO LLP 2700 CAMINO RAMON STE 350 SAN RAMON CA 945835004 990 2022-01-01 204284925 QUANTUM LEAP HEALTHCARE COLLABORATIVE QUAN 8558660505 499 ILLINOIS AVE 200 SAN FRANCISCO CA 94158 JAMES PALAZZOLO CEO 8558660505 2023-11-15 1 JAMES PALAZZOLO 999009999 1 MATTHEW PETROSKI P00853132 9257902600 2023-11-14 0 AAL1 IAL1 2022 2023-04-26 12:10:37Z JAMES PALAZZOLO 499 ILLINOIS AVE 200 SAN FRANCISCO CA 94158 130915690 0 X WWW.QUANTUMLEAPHEALTH.ORG X 2005 CA THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE (CONTINUED ON SCH. O)MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 13 12 113 12 0 0 36277016 18937275 19833945 27865728 31363 450842 0 0 56142324 47253845 25791 0 0 0 10422634 16155579 0 0 253049 33307137 31084816 43755562 47240395 12386762 13450 64443428 60913948 33840706 30870765 30602722 30043183 X THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT. 0 0 22845603 26360608 I-SPY TRIALS: QUANTUM LEAP SPONSORS THE I-SPY TRIALS (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS). I-SPY HAS BEEN RE-ENGINEERING THE APPROACH TO CLINICAL TRIALS, WITH A GOAL OF GETTING THE RIGHT DRUG TO THE RIGHT PATIENT AT THE TIME WHEN THEY WILL BENEFIT MOST, AND TO ACHIEVE THIS FASTER THAN POSSIBLE IN PREVIOUS TRIAL MODELS. ADDITIONALLY, I-SPY AIMS TO SIGNIFICANTLY REDUCE THE OVERALL COST, TIME, AND NUMBER OF PATIENTS REQUIRED TO BRING NEW DRUGS TO MARKET. THE I-SPY TRIAL PROGRAM INTEGRATES AND LINKS PHASE I (I-SPY PHASE 1), PHASE II (I-SPY 2), AND FUTURE PHASES TO BUILD A PIPELINE OF NOVEL AGENTS AND ACCELERATE THE PROCESS OF IDENTIFYING THE SUBSET OF HIGH-RISK BREAST CANCER PATIENTS THAT WILL BENEFIT FROM THESE NEW AGENTS, AND GET THESE DRUG INTO THE CLINIC IN A TIMELY MANNER. 20050960 554000 DURING FISCAL YEAR 2020, THE I-SPY COVID TRIAL AN ADAPTIVE PLATFORM TRIAL, WAS DESIGNED TO RAPIDLY SCREEN AND CONFIRM HIGH IMPACT TREATMENTS TO REDUCE MORTALITY AND TIME ON VENTILATORS. THIS WORK IS INDEPENDENT AND EQUALLY AS IMPORTANT AS VACCINE EFFORTS. I-SPY COVID TRIAL FOCUSES ON THOSE PATIENTS WHOSE REACTIONS TO THE VIRUS MAKE THEM CRITICALLY ILL AND, IN MANY CASES, RESULTS IN DEATH. THE PRIMARY FOCUS OF THE TRIAL WAS TO IDENTIFY PROMISING DRUGS THAT EITHER NEUTRALIZE THE VIRUS, HELP HEAL THE LUNG DAMAGE FROM THE VIRUS (CAUSED BY ADULT RESPIRATORY DISTRESS SYNDROME OR (ARDS) OR TO CHANGE THE IMMUNE SYSTEM REACTION WHICH RESULTS IN ILLNESS (FOR YOUNGER PEOPLE, THIS IS ESPECIALLY IMPORTANT). THE TRIAL OPENED JUNE 2020 AND WILL CONTINUE TO RUN UNTIL A DRUG OR COMBINATIONS OF DRUGS, IS FOUND THAT PREVENTS THE NECESSITY FOR VENTILATION TREATMENT AND ELIMINATES DEATH FROM THE DISEASE. 1207919 62500 BREAST CANCER TRIALS (BCT) - LAUNCHED IN 2008, FOLLOWING A SUCCESSFUL UCSF-NCI SPONSORED RESEARCH PILOT, ITS MISSION IS TO MAKE PATIENT CONSIDERATION OF TRIALS THE NORM VS. THE EXCEPTION. WE BELIEVE THAT ALL PATIENTS SHOULD HAVE ACCESS TO THE LATEST MEDICAL KNOWLEDGE ABOUT BREAST CANCER TREATMENT AS WELL AS THE OPPORTUNITY TO ADVANCE BREAST CANCER RESEARCH. BCT LISTS OVER 600 STUDIES FOR PEOPLE WITH NEWLY DIAGNOSED BREAST CANCER, METASTATIC DISEASE, OR POST-TREATMENT SURVIVORS. IT INCLUDES INNOVATIVE TRIALS OF TARGETED AND IMMUNOTHERAPIES AS WELL AS OBSERVATIONAL STUDIES LOOKING AT QUALITY OF LIFE, GENETIC MUTATIONS, AND BREAST CANCER SURVIVORSHIP, ACCOMPANIED BY EASY-TO-READ TRIAL SUMMARIES. 277797 888620 277797 888620 44382279 1 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 1 46 0 1 113 1 0 0 0 0 0 0 0 0 0 0 0 0 X 13 12 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X X X THE ORGANIZATION 8558660505 499 ILLINOIS AVE 200 SAN FRANCISCO CA 94158 DAVE MANDELKERN CHAIRMAN 12.00 X X 120000 0 0 LAURA ESSERMAN DIRECTOR, COFOUNDER 20.00 X X 0 0 0 JEFFREY PFEFFER DIRECTOR, COFOUNDER 0.50 X X 0 0 0 SUSAN FOLEY TREASURER 0.50 X 0 0 0 ANNA BARKER DIRECTOR 0.50 X 0 0 0 LUCAS DE BREED DIRECTOR 0.50 X 0 0 0 MICHELE MARKUS DIRECTOR 0.50 X 0 0 0 ROBERT PATTERSON DIRECTOR 0.50 X 0 0 0 ROBYN LAWRIE RUTLEDGE DIRECTOR 0.50 X 0 0 0 GREGORY C SIMON DIRECTOR 0.50 X 0 0 0 MARK SIMON DIRECTOR 0.50 X 0 0 0 N MARCUS THYGESON DIRECTOR 0.50 X 0 0 0 LAMBERT VAN DER WALDE DIRECTOR 0.50 X 0 0 0 KATHRYN WATSON-FEINER VICE PRESIDENT OF FINANCE AND ADMINISTRATION 60.00 X 305989 0 12429 JAMES PALAZZOLO CEO 60.00 X 508333 0 40413 ADAM ASARE CHIEF DATA OFFICER 60.00 X 212462 0 11095 KARYN DIGIORGIO CHIEF COLLABORATION OFFICER 60.00 X 278506 0 33256 TRACEY HEATHER DIRECTOR OF DEVELOPMENT 60.00 X 231040 0 44304 PAUL HENDERSON SR. DIRECTOR OF COLLABORATIONS 60.00 X 231615 0 44883 MARIA PITSIOUNI DIRECTOR, CLINICAL OPERATIONS ONCOLOGY 60.00 X 216516 0 34843 SARA HORTON EXECUTIVE DIRECTOR, ACCESS & DIVERSITY 60.00 X 235513 0 4250 2339974 0 225473 64 0 1 0 NCOMPASS RECRUITING SERVICES 3247 WARREN LANE EL DORADO HILLS CA 95762 STAFF RECRUITMENT 664184 OWL BROOK ASSOCIATES LLC PO BOX 1390 ASHLAND NH 03217 TECHNOLOGY AND WEBSITE 615140 SLALOM LLC 821 2ND AVE SUITE 1900 SEATTLE WA 98104 TECHNOLOGY AND WEBSITE 363343 URBAN VENTURE GROUP INC 6848 MERWOOD ST COLUMBUS OH 43235 ADMINISTRATIVE CONSULTING 297000 BURR PILGERMAYER 600 CALIFORNIA ST SUITE 600 SAN FRANCISCO CA 94108 AUDIT AND TAX 177192 12 17468384 1468891 741884 18937275 CLINICAL TRIAL CONTRAC 541511 26914608 26914608 CONSULTING AND RESEARC 541511 951120 951120 27865728 517557 517557 83595130 83661845 -66715 -66715 -66715 47253845 27865728 0 450842 1090719 1036184 54535 12102560 10702036 1217124 183400 314326 278211 31412 4703 1750484 1554396 171056 25032 897490 798244 86709 12537 143333 143333 465350 465350 5974 5974 1043036 967318 72380 3338 116000 102723 12995 282 1277193 1190520 79765 6908 8167801 8052394 103322 12085 448362 448362 292248 174853 115714 1681 289206 271836 16378 992 230567 216719 13057 791 1123 930 157 36 95350 82435 12227 688 56511 54143 2122 246 PROGRAM MANAGEMENT 10420794 10420794 RESEARCH SITES 6117052 6117052 RESEARCH 1904475 1904475 OTHER 10441 8654 1457 330 47240395 44382279 2605067 253049 3320860 4269894 44752067 4943974 1775471 1438761 4913529 11320172 2884 1802060 636230 324892 172229 210502 152663 7666055 37862213 0 290041 64443428 60913948 25408456 18472283 8432250 10935289 0 1463193 33840706 30870765 X 28731090 29720498 1871632 322685 30602722 30043183 64443428 60913948 13450 -575672 2683 0 X 0 1 X 1 0 X 1203352 1876103 12652517 36277016 19517275 71526263 1203352 1876103 12652517 36277016 19517275 71526263 71526263 121682 87600 31363 517557 758202 72284465 0.98950 0.96860 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 88018 88018 236874 172229 64645 152663 OTHER LONG TERM LIABILITIES 1463193 1463193 46678172 -575673 -575673 47253845 0 47253845 47240395 0 47240395 0 47240395 X X X X X 0 0 0 0 0 0 0 1 0 JAMES PALAZZOLO CEO 433333 0 75000 0 0 0 4167 0 36246 0 548746 0 0 0 KATHRYN WATSON-FEINER VICE PRESIDENT OF FINANCE AND ADMINI 296388 0 9601 0 0 0 9724 0 2705 0 318418 0 0 0 KARYN DIGIORGIO CHIEF COLLABORATION OFFICER 269680 0 8826 0 0 0 6855 0 26401 0 311762 0 0 0 PAUL HENDERSON SR. DIRECTOR OF COLLABORATIONS 224112 0 7503 0 0 0 8891 0 35992 0 276498 0 0 0 TRACEY HEATHER DIRECTOR OF DEVELOPMENT 223553 0 7487 0 0 0 8314 0 35990 0 275344 0 0 0 MARIA PITSIOUNI DIRECTOR, CLINICAL OPERATIONS ONCOLO 211380 0 5136 0 0 0 8661 0 26182 0 251359 0 0 0 SARA HORTON EXECUTIVE DIRECTOR, ACCESS & DIVERSI 235513 0 0 0 0 0 2750 0 1500 0 239763 0 0 0 ADAM ASARE CHIEF DATA OFFICER 205882 0 6580 0 0 0 8499 0 2596 0 223557 0 0 0 PART I, LINE 7 DISCRETIONARY BONUSES ARE APPROVED BY THE BOARD OF DIRECTORS. DAVID MANDELKERN DIRECTOR 120094 MANAGEMENT ADVIOSRY SERVICES 0 X 1 741884 FMV 0 0 0 0 PART I, COLUMN (B): THIS NUMBER REPRESENTS THE NUMBER OF CONTRIBUTORS, NOT THE NUMBER OF ITEMS CONTRIBUTED. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS PREPARED BY AN INDEPENDENT CPA FIRM IN CONJUNCTION WITH THE ORGANIZATION'S DIRECTOR OF FINANCE. A DRAFT OF FORM 990 IS REVIEWED BY THE DIRECTOR OF FINANCE, AND CORRECTIONS/MODIFICATIONS ARE MADE BY THE OUTSIDE CPA. THE REVISED DRAFT IS THEN REVIEWED BY THE DIRECTOR OF FINANCE. ANY CONCERNS ARE RAISED WITH THE CPA FIRM AND A CONSENSUS IS ACHIEVED. BOARD MEMBERS ARE SENT A COPY OF THE TAX RETURN PRIOR TO FILING FOR THEIR REVIEW. THE RETURN IS THEN FINALIZED AND ELECTRONICALLY FILED WITH THE TAXING AUTHORITIES. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS PRESENTED AND REVIEWED ANNUALLY. EACH BOARD MEMBER IS REQUIRED TO ACKNOWLEDGE IN WRITING THAT NO CONFLICT EXISTS. FORM 990, PART VI, SECTION B, LINE 15 COMPENSATION OF THE PRESIDENT OF THE ORGANIZATION WAS DETERMINED AND APPROVED BY VOTE OF THE BOARD OF DIRECTORS. PERSONNEL OF UCSF REVIEWED JOB REQUIREMENTS AGAINST TECHNICAL ABILITIES OF SUBCONTRACTORS AND DETERMINED WHETHER OR NOT THEY MATCHED. ALL SUBCONTRACTORS WERE ENGAGED AT BELOW-MARKET RATES. FORM 990, PART VI, SECTION C, LINE 19 ALL GOVERNING DOCUMENTS, AUDITED FINANCIAL STATEMENTS AND FORM 990, RETURN OF ORGANIZATION EXEMPT FROM INCOME TAX, ARE PROVIDED UPON WRITTEN REQUEST OR THROUGH THE QUANTUM LEAP HEALTHCARE COLLABORATIVE WEBSITE, AS WELL AS TO ANYONE WHO REQUESTS THEM IN WRITING. THEY ARE ALSO AVAILABLE FOR INSPECTION AT THE QLHC OFFICE DURING NORMAL BUSINESS HOURS.